NASDAQ:URGN Urogen Pharma (URGN) Stock Price, News & Analysis $28.89 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$28.90 +0.01 (+0.03%) As of 05/22/2026 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Urogen Pharma Stock (NASDAQ:URGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Urogen Pharma alerts:Sign Up Key Stats Today's Range$28.80▼$30.2050-Day Range$17.00▼$31.3352-Week Range$3.61▼$32.37Volume364,372 shsAverage Volume920,799 shsMarket Capitalization$1.41 billionP/E RatioN/ADividend YieldN/APrice Target$36.67Consensus RatingModerate Buy Company Overview UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists. The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer. Jelmyto represents the first FDA-approved therapy for this indication, offering a minimally invasive, kidney-sparing alternative to surgery. Beyond Jelmyto, UroGen’s pipeline includes UGN-102, an investigational mitomycin solution under study for interstitial cystitis/bladder pain syndrome, and earlier-stage programs targeting other urologic and ophthalmic conditions leveraging the RTGel platform. UroGen markets its products primarily in the United States and is pursuing regulatory submissions in Europe and other global regions. The company’s management team is led by Co-Founder and Chief Executive Officer Tomer Kariv, supported by Chief Operating Officer Vas Narasimhan and Chief Medical Officer Philip Isaacs, among others. UroGen collaborates with key opinion leaders in urology to advance its clinical programs and expand patient access to novel in-office therapies.AI Generated. May Contain Errors. Read More Urogen Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks67th Percentile Overall ScoreURGN MarketRank™: Urogen Pharma scored higher than 67% of companies evaluated by MarketBeat, and ranked 259th out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingUrogen Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 7 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialUrogen Pharma has a consensus price target of $36.67, representing about 26.9% upside from its current price of $28.89.Amount of Analyst CoverageUrogen Pharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Urogen Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Urogen Pharma are expected to grow in the coming year, from ($0.98) to $1.40 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Urogen Pharma is -10.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Urogen Pharma is -10.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Urogen Pharma's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted15.59% of the float of Urogen Pharma has been sold short.Short Interest Ratio / Days to CoverUrogen Pharma has a short interest ratio ("days to cover") of 8.88.Change versus previous monthShort interest in Urogen Pharma has recently decreased by 7.54%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldUrogen Pharma does not currently pay a dividend.Dividend GrowthUrogen Pharma does not have a long track record of dividend growth. News and Social Media2.0 / 5News SentimentN/A News SentimentUrogen Pharma has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Urogen Pharma this week, compared to 6 articles on an average week.Search InterestOnly 2 people have searched for URGN on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows3 people have added Urogen Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Urogen Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders4.70% of the stock of Urogen Pharma is held by insiders.Percentage Held by Institutions91.29% of the stock of Urogen Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Urogen Pharma's insider trading history. Receive URGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Urogen Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. URGN Stock News HeadlinesHow UGN-103’s Strong Phase 3 UTOPIA Data Could Shape UroGen Pharma (URGN) InvestorsMay 23 at 1:09 AM | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Urogen Pharma (URGN) and CervoMed (CRVO)May 18, 2026 | theglobeandmail.comThe SpaceX filing is public. The window is closing.SpaceX just filed its S-1. The IPO is confirmed for June 12 - $75 billion, ticker SPCX, potentially the largest in history. The 21-bank syndicate has already locked up shares, so retail investors won't get access. But the S-1 exposed one publicly traded company Musk cannot operate without - and it's still cheap. Dylan Jovine is releasing the ticker free before June 12 changes the price. | Behind the Markets (Ad)UroGen Pharma Ltd. (URGN) Discusses Real-World Experiences and Outcomes With ZUSDURI for Recurrent Bladder Cancer TranscriptMay 17, 2026 | seekingalpha.comUroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBCMay 15, 2026 | globenewswire.comUrogen Pharma (NASDAQ:URGN) Given Consensus Rating of "Moderate Buy" by BrokeragesMay 15, 2026 | americanbankingnews.comUroGen Pharma Ltd. (URGN) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION TrialMay 13, 2026 | globenewswire.comSee More Headlines URGN Stock Analysis - Frequently Asked Questions How have URGN shares performed this year? Urogen Pharma's stock was trading at $23.42 at the start of the year. Since then, URGN shares have increased by 23.4% and is now trading at $28.89. How were Urogen Pharma's earnings last quarter? Urogen Pharma (NASDAQ:URGN) issued its earnings results on Thursday, May, 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.48) by $0.01. The firm had revenue of $50.96 million for the quarter, compared to analyst estimates of $44.83 million. Read the conference call transcript. When did Urogen Pharma IPO? Urogen Pharma (URGN) raised $58 million in an initial public offering on Thursday, May 4th 2017. The company issued 4,473,373 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company acted as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers. Who are Urogen Pharma's major shareholders? Top institutional investors of Urogen Pharma include SG Americas Securities LLC (3.41%), ADAR1 Capital Management LLC (0.81%), Healthcare of Ontario Pension Plan Trust Fund (0.79%) and Rice Hall James & Associates LLC (0.59%). Insiders that own company stock include Mark Schoenberg, Jason Drew Smith and Chris Degnan. View institutional ownership trends. How do I buy shares of Urogen Pharma? Shares of URGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Urogen Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Urogen Pharma investors own include Voyager Therapeutics (VYGR), AUO (AUOTY), Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings5/07/2026Today5/25/20267th Annual Oncology Innovation Summit: Insights for ASCO & EHA5/26/2026AGM 20266/22/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 URGN's financial health is in the Green zone, according to TradeSmith. URGN has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:URGN CIK1668243 Webwww.urogen.com Phone(646) 768-9780FaxN/AEmployees200Year Founded2004Price Target and Rating Average Price Target for Urogen Pharma$36.67 High Price Target$47.00 Low Price Target$16.00 Potential Upside/Downside+26.9%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($2.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$153.49 million Net Margins-94.83% Pretax Margin-98.45% Return on EquityN/A Return on Assets-62.85% Debt Debt-to-Equity RatioN/A Current Ratio4.69 Quick Ratio4.28 Sales & Book Value Annual Sales$109.79 million Price / Sales12.82 Cash FlowN/A Price / Cash FlowN/A Book Value($2.55) per share Price / Book-11.33Miscellaneous Outstanding Shares48,720,000Free Float46,432,000Market Cap$1.41 billion OptionableOptionable Beta1.58 Social Links Don't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:URGN) was last updated on 5/26/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredThe S-1 just dropped. 22 days left.The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...Behind the Markets | SponsoredMy crisis of conscienceEmmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...Porter & Company | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredYour book attachedBill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...Profits Run | SponsoredTrump Admin to Pump $1 Billion into this “Off-the-Radar” AI StockThe U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...InvestorPlace | SponsoredOpportunity Forming in a U.S. Supply-Chain Weak Spot?America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...i2i Marketing Group, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Urogen Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share Urogen Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
